Browse the evidence

There was a trend towards greater muscle mass adaptations in the BFR-CH group, but these findings showed no statistical significance.

While BFR-CH may show promise, practitioners should be cautious as the results are not statistically significant.

Whey protein supplementation does not increase lean mass in studies without energy restriction.

Whey protein may not be effective for increasing lean mass without accompanying energy restriction.

Understanding the hedonic mechanisms mediated by gut peptide action could advance development of potential therapeutic strategies for the treatment of obesity and its comorbidities.

Research on gut peptides may lead to new obesity treatments.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative hematoma (RR: 0.440; P = 0.023).

Consideration of GLP-1 RA may help in minimizing hematoma risks in surgical patients.

MijnEetmeter food diary moderately underestimates intakes of energy and some nutrients and food groups.

Practitioners should be aware that MijnEetmeter may not provide accurate dietary intake assessments.

Correlations between 3-day mean intakes for energy and six key nutrients were above 0.7 except for sodium intake.

High correlations suggest that MijnEetmeter can be a reliable tool for tracking most nutrients.

Only 8% of cardiac rehabilitation programs in the United States currently deliver behavioral weight programs.

Practitioners should be aware that a majority of cardiac rehabilitation programs do not currently offer behavioral weight loss support.

Having a normal body weight does not automatically imply preserved metabolic health.

Practitioners should assess metabolic health beyond just body weight.

There is evidence for the presence of metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) phenotypes.

Understanding these phenotypes can guide personalized treatment approaches.

Short-acting GLP-1 receptor agonists are associated with an increased risk of erosive reflux disease (ERD) with a hazard ratio (HR) of 1.215.

Clinicians should be cautious when prescribing short-acting GLP-1 RAs to patients with type 2 diabetes due to the increased risk of ERD.

Short-acting GLP-1 receptor agonists are associated with an increased risk of oesophageal stricture with a hazard ratio (HR) of 1.284.

Healthcare providers should monitor for signs of oesophageal stricture in patients using short-acting GLP-1 RAs.

Short-acting GLP-1 receptor agonists are associated with an increased risk of Barrett's esophagus with dysplasia with a hazard ratio (HR) of 1.505.

Clinicians should be aware of the potential risk of Barrett's esophagus with dysplasia in patients prescribed short-acting GLP-1 RAs.

Increased consumption of carbohydrates is associated with obesity and increased risk of mortality.

Reducing carbohydrate intake may be beneficial for weight management and reducing mortality risk.

Machine learning techniques can enhance the ability to forecast obesity outcomes accurately.

Implementing machine learning can lead to better early detection and prediction of obesity.

The exercise goal of 10,000 steps/day was unachievable for the participants.

Practitioners should consider setting realistic exercise goals for pregnant women to enhance adherence.

GLP-1 receptor agonists (GLP-1RAs) are associated with accelerated facial aging and altered skin health.

Clinicians should be aware of the potential for accelerated facial aging in patients treated with GLP-1RAs.

The accelerated facial aging observed in GLP-1RA patients is multifactorial, involving loss of dermal and subcutaneous white adipose tissue.

Understanding the multifactorial nature of aging can guide treatment approaches for affected patients.

Treatment strategies targeting adipose-derived stem cell (ADSC) stimulation may mitigate facial aging effects from GLP-1RAs.

Clinicians may consider ADSC-targeted treatments to improve skin health in patients using GLP-1RAs.

More studies are needed to support the long-term effects of long-acting amylin analogues in relevant populations.

Practitioners should be aware that while promising, the long-term efficacy of these treatments is not yet established.

The analysis was limited to studies using dual-energy X-ray absorptiometry (DXA) for measuring fat-free mass.

Practitioners should be aware of the limitations of DXA in assessing body composition.

GLP-1RAs may have renal benefits driven by new-onset macroalbuminuria.

GLP-1RAs may be considered for patients with T2D who also have renal concerns, particularly regarding macroalbuminuria.

The relationship between BMI and LDL cholesterol change was not observed on higher-carbohydrate diets.

Practitioners should consider that the effects of BMI on LDL cholesterol may differ with carbohydrate intake levels.

Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.

Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.

The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.

Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.